PBAC's latest decision on Alendronate sodium with colecalciferol: Recommended with restriction (2006). Considered for Initial treatment for established osteoporosis in patients with fracture due to minimal trauma, in patients who require a supplemental intake of vitamin D. Continuing treatment for established osteoporosis in patients with fracture due to minimal trauma, where the patient has previously been issued with an authority prescription for this drug.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2006
Submissions
1
2006 → 2006
Eligible population
patients with established osteoporosis who may require vitamin D supplementation
Therapy area
Endocrinology
Line of therapy
Initial treatment, Continuing treatment
Evidence base
RCT
Key trials
Protocol 227
Comparator
alendronate 70 mg once weekly
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no economic evaluation presented as submission requested same price as comparator without premium